The European Society for Medical Oncology (ESMO) - a professional society representing over 50,000 members globally - welcomes the European Commissions proposal for a targeted revision of Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR).
ESM
European Society for Medical Oncology (ESMO)
NGO · Switzerland · EU Transparency Register 947929324977-41
16
positions filed
in the 665 files tracked
11
legislative files
of 665 tracked
13
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 410 trade unions and professional associations on this site, they rank #41 by legislative files engaged, a count of participation, not a measure of influence.
4
declared lobbying FTE
self-declared
€400K+
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2016
in the register since
Declares membership of
- ESMO is a full member of the Union of International Cancer Control (UICC, Geneva) and the European Health Alliance on…
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Trade unions and professional associations
- Head office
- Lugano, Switzerland
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track European in PolicySpeak: request access →
Work at European Society for Medical Oncology (ESMO)? so we know who speaks for it.
Their record over time
European Society for Medical Oncology (ESMO) filed 16 positions between 27 Apr 2021 and 29 Sept 2026, across 11 of the 665 legislative files tracked here, attaching a full position paper 13 times.
2021 · 2 filed2022 · 2 filed2023 · 3 filed2025 · 4 filed2026 · 5 filed
What they argued
The European Society for Medical Oncology (ESMO) - a professional society representing over 45,000 members from 179 countries and territories - commends the Commission for its efforts to resolve the existential threat to oncological research in the EU, posed by the implementation of Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR).
The European Society for Medical Oncology (ESMO), representing more than 45,000 members globally, welcomes the opportunity to provide feedback on the proposal for the Regulation establishing Horizon Europe (10th EU Framework Programme) as part of the larger consultation exercise on the post-2027 Multiannual Financial Framework (EU funding for competitiveness).
The European Society for Medical Oncology (ESMO), representing over 45,000 members globally, welcomes the opportunity to provide feedback on the next EU Multiannual Financial Framework (MFF). The draft MFF architecture foresees a European Competitiveness Fund (ECF) consolidating around 14 programmesincluding potentially EU4Healthinto broad competitiveness windows.
The European Society for Medical Oncologys (ESMO) Rare Cancers Working Group (RCWG) is a multi-stakeholder partnership which brings together scientific societies, patient and research organisations, healthcare and education providers, and industry.
The European Society for Medical Oncology (ESMO) is one of the leading professional organisations for medical oncology, with more than 33,000 members from over 170 countries. ESMO is committed to preventing new cancer cases, improving the quality of cancer care and promoting equal access to optimal treatments for all cancer patients.
Representing more than 25,000 oncology professionals from over 160 countries, ESMO welcomes this important consultation. In light of this, we recommend the following: 1. Ensure access: • HTA: ESMO believes that unifying HTA across Europe through joint clinical assessments will contribute to improving access to high quality medicines.
The European Society for Medical Oncology (ESMO) welcomes the proposal for a Regulation laying down harmonised rules on Artificial Intelligence. While the intention of the Regulation is welcomed, ESMO is concerned regarding the potential impact of this Regulation on the usage of artificial intelligence technologies for the purposes of health research and healthcare practice.
The European Society for Medical Oncology (ESMO) - a professional society representing over 50,000 members globally - welcomes the Commissions proposal for a European Biotech Act as a timely initiative to strengthen Europes attractiveness for biomedical research and innovation, including in oncology.
The European Society for Medical Oncology (ESMO) welcomes the ambition of the European Commission to launch a proposal for a European Biotech Act. Please find the input from ESMO to the Call for Evidence attached. For further information, please contact: [email removed]
Representing more than 25,000 oncology professionals from over 160 countries, the European Society for Medical Oncology (ESMO) welcomes the proposal for the European Health Data Space (EHDS) and its intention to improve patient access to their health data and facilitate the use of health data for research and innovation.
The European Society for Medical Oncology (ESMO), representing over 50,000 oncology professionals globally, welcomes the European Commissions proposal for a comprehensive EU Cardiovascular Health Plan. Cardiovascular diseases remain the leading cause of death in the EU, while cancer follows as the second leading cause, responsible for 1.3 million deaths annually in the EU.
ESMO Feedback - Proposal for Revising and Merging the EU Ambient Air Quality Directives The European Society for Medical Oncology (ESMO) - representing more than 28,000 oncology professionals from over 160 countries - welcomes the European Commission’s ambition to achieve zero air pollution by 2050 by revising and merging the Ambient Air Quality Directives.
Opening of the attached position paper · the full paper is on the Commission’s record (source link above)
The European Society for Medical Oncology (ESMO), representing over 50,000 members globally, welcomes the publication of the draft Implementing Act setting out the technical and functional framework for the HealthData@EU infrastructure under the European Health Data Space (EHDS) as well as the specifications of the IT tool for enforcement transparency.
The European Society for Medical Oncology (ESMO), representing over 50,000 members globally, welcomes the publication of the draft Implementing Act laying down the minimum metadata elements and their characteristics to be provided by health data holders for dataset descriptions for the secondary use of electronic health data under the European Health Data Space (EHDS) Regulation.
The European Society for Medical Oncology (ESMO), as the leading professional organisation for medical oncology representing more than 25,000 oncology professionals from over 160 countries worldwide, welcomes the efforts of the European Commission to address the health-related risks stemming from asbestos by proposing to revise the Asbestos at Work Directive.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put European Society for Medical Oncology (ESMO) next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 234.
Is this your organization?
Everything on this page comes from European Society for Medical Oncology (ESMO)’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.